Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Panobinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 0.87 |
| ▸ | HDAC2 known ✓ | Q92769 | 12/20 | 0.87 |
| ▸ | HDAC3 known ✓ | O15379 | 12/20 | 0.87 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.87 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.87 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.87 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.87 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.87 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.87 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.87 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.87 |
| ▸ | NCOR2 | Q9Y618 | 10/20 | 0.87 |
| ▸ | TET3 | O43151 | 1/20 | 0.87 |
| ▸ | BRD4 | O60885 | 1/20 | 0.87 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.87 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.87 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.87 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panobinostat SCHEMBL30235437 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315067 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL29358399 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316088 | 0.99 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316081 | 0.99 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL183197 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL164801 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL22773814 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL20165843 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL436875 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018092151-A1 | PROCESS FOR THE PREPARATION OF 2-(E)-N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL) ETHYL]AMINO]METHYL]PHENYL]-2-PROPENAMIDE 2-HYDROXYPROPANOIC ACID (1:1) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-24 | — | — | WO | claimed |
| EP-4378476-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023008459-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2023-02-02 | — | — | WO | disclosed |
| CN-106866491-B | Panobinostat lactate crystal form I and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-106866492-B | Panobinostat lactate crystal form II and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2018092151-A1 | PROCESS FOR THE PREPARATION OF 2-(E)-N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL) ETHYL]AMINO]METHYL]PHENYL]-2-PROPENAMIDE 2-HYDROXYPROPANOIC ACID (1:1) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-24 | — | — | WO | disclosed |
| EP-2032532-B1 | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-7989639-B2 | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090187029-A1 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | PHARMA& SCHWEIZ GMBH (CH) | 2009-07-23 | — | — | US | disclosed |
| EP-2032532-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-Ý4-ÝÝÝ2-(2-METHYL-1H-INDOL-3-YL)ETHYL¨AMINO¨METHYL¨PHENYL¨-2E-2-PROPENAMIDE | Novartis AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146717-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187029-A1 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | HTR3E, HTR3A, PNMT | HDAC1 3327/4885HDAC2 1813/4885HDAC3 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.